Aquatic Capital Management LLC Acquires New Stake in IDEXX Laboratories, Inc. $IDXX

Aquatic Capital Management LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 8,299 shares of the company’s stock, valued at approximately $5,302,000.

A number of other institutional investors have also added to or reduced their stakes in IDXX. EverSource Wealth Advisors LLC increased its position in shares of IDEXX Laboratories by 2.5% in the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after purchasing an additional 15 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in shares of IDEXX Laboratories by 4.4% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after buying an additional 16 shares during the last quarter. Moss Adams Wealth Advisors LLC raised its position in shares of IDEXX Laboratories by 3.3% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after buying an additional 17 shares in the last quarter. Private Trust Co. NA raised its position in shares of IDEXX Laboratories by 9.4% during the 3rd quarter. Private Trust Co. NA now owns 209 shares of the company’s stock valued at $134,000 after buying an additional 18 shares in the last quarter. Finally, Ascent Group LLC lifted its holdings in shares of IDEXX Laboratories by 2.9% during the 3rd quarter. Ascent Group LLC now owns 632 shares of the company’s stock worth $404,000 after acquiring an additional 18 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,758 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the transaction, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sophie V. Vandebroek sold 1,464 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the transaction, the director directly owned 648 shares of the company’s stock, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,957 shares of company stock worth $29,862,109 over the last ninety days. Insiders own 0.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on IDXX. BTIG Research reduced their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Piper Sandler reduced their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Finally, Barclays dropped their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Trading Up 2.2%

NASDAQ IDXX opened at $586.37 on Tuesday. The firm has a market cap of $46.69 billion, a PE ratio of 44.86, a price-to-earnings-growth ratio of 3.48 and a beta of 1.66. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The stock has a 50-day moving average of $656.25 and a 200-day moving average of $666.45. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.